Alpine Global Management’s Matinas BioPharma MTNB Stock Holding History

Alpine Global Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-27	Closed	-$12K	–	385
2020 Q1	$12K	Sell	27 -54	-67%	-$48.9K	﹤0.01%	228
2019 Q4	$138K	Buy	+81	New	+$70.4K	0.03%	344
2019 Q1	–	Sell	-550	Closed	-$245K	–	171
2018 Q4	$245K	Buy	+550	New	+$324K	0.06%	173
2018 Q3	–	Sell	-168	Closed	-$55K	–	91
2018 Q2	$55K	Buy	+168	New	+$72.8K	0.03%	63

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Alpine Global Management's MTNB Position: Q2 2020 in Review

Alpine Global Management sold out of Matinas BioPharma (MTNB) in Q2 2020, closing a stake of 27 shares — an estimated $12K sold.

Alpine Global Management first reported a position in MTNB in Q2 2018 and held it in 4 quarters. The position peaked at $245K in Q4 2018. 62 funds tracked by Wall St. Rank hold MTNB as of Q2 2020.

Alpine Global Management reported no remaining Matinas BioPharma position as of Q2 2020 after selling out during the quarter.
Alpine Global Management sold 27 Matinas BioPharma shares in Q2 2020, an estimated $12K.
Alpine Global Management first reported a position in Matinas BioPharma in Q2 2018 and held it in 4 quarters.
Alpine Global Management's Matinas BioPharma position peaked at $245K in Q4 2018.
62 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2020.

Based on Alpine Global Management's 13F filing for Q2 2020, filed 14 Aug 2020.